Free Trial

Metsera 3/26/2025 Earnings Report

Metsera logo
$18.18 +4.18 (+29.86%)
As of 04:00 PM Eastern

Metsera EPS Results

Actual EPS
-$3.52
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Metsera Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Metsera Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Remove Ads

Metsera Earnings Headlines

Bank of America Securities Remains a Buy on Metsera, Inc. (MTSR)
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).
Metsera reports Q4 EPS ($3.52) vs. (94c) last year
Metsera sees cash runway into 2027
See More Metsera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metsera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metsera and other key companies, straight to your email.

About Metsera

Metsera (NASDAQ:MTSR) is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

View Metsera Profile

More Earnings Resources from MarketBeat